JNK-IN-8: a novel covalent inhibitor targeting JNK signaling in triple-negative breast cancer

被引：0
|
作者：
Xie, Xuemei [1 ]
Kaoud, Tamer S. [2 ]
Edupunganti, Ramakrishna [2 ]
Zhang, Tinghu [3 ]
Kogawa, Takahiro [1 ]
Chauhan, Gaurav B. [1 ]
Gray, Nathanael S. [3 ]
Bartholomeusz, Chandra [1 ]
Dalby, Kevin N. [2 ]
Ueno, Naoto T. [1 ]
机构：
[1] UT MD Anderson Canc Ctr, Houston, TX USA
[2] Univ Texas Austin, Austin, TX 78712 USA
[3] Harvard Univ, Sch Med, Boston, MA USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-750
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
750
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Covalent JNK inhibitor, JNK-IN-8, suppresses tumor growth in triple-negative breast cancer in part by activating lysosome biogenesis and autophagy via TFEB and TFE3
    Soleimani, Milad
    Kaoud, Tamer
    Somma, Alex
    Bustamante, Jorge
    Wylie, Dennis C.
    Holay, Nisha
    Looney, Agnieszka
    Giri, Uma
    Triplett, Todd
    Kowalski-Muegge, Jeanne
    Dalby, Kevin N.
    Eckhardt, S. Gail
    Van den Berg, Carla
    CANCER RESEARCH, 2022, 82 (12)
  • [2] Covalent JNK Inhibitor, JNK-IN-8, Suppresses Tumor Growth in Triple-Negative Breast Cancer by Activating TFEB- and TFE3-Mediated Lysosome Biogenesis and Autophagy
    Soleimani, Milad
    Somma, Alexander
    Kaoud, Tamer
    Goyal, Ria
    Bustamante, Jorge
    Wylie, Dennis C.
    Holay, Nisha
    Looney, Agnieszka
    Giri, Uma
    Triplett, Todd
    Dalby, Kevin
    Kowalski, Jeanne
    Eckhardt, S. Gail
    Van Den Berg, Carla
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (10) : 1547 - 1560
  • [3] The covalent JNK inhibitor, JNK-IN-8, synergizes with lapatinib to cause cell death in basal-like breast cancer cell lines
    Ebelt, N. D.
    Van den Berg, C. L.
    CANCER RESEARCH, 2016, 76
  • [4] A c-Jun N-terminal kinase inhibitor, JNK-IN-8, sensitizes triple negative breast cancer cells to lapatinib
    Ebelt, Nancy D.
    Kaoud, Tamer S.
    Edupuganti, Ramakrishna
    Van Ravenstein, Sabrina
    Dalby, Kevin N.
    Van den Berg, Carla L.
    ONCOTARGET, 2017, 8 (62): : 104894 - 104912
  • [5] Suppression of triple-negative breast cancer tumorigenesis by targeting cancer stem cells through JNK/Notch1 signaling inhibition
    Xie, Xuemei
    Kaoud, Tamer S.
    Edupunganti, Ramakrishna
    Zhang, Tinghu
    Kogawa, Takahiro
    Chauhan, Gaurav B.
    Giannoukos, Dionysios N.
    Qi, Yuan
    Tripathy, Debu
    Gray, Nathanael S.
    Dalby, Kevin N.
    Bartholomeusz, Chandra
    Ueno, Naoto T.
    CANCER RESEARCH, 2015, 75
  • [6] Targeting triple-negative breast cancer
    Kirkpatrick, Peter
    NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (01) : 21 - 21
  • [7] Targeting triple-negative breast cancer
    Peter Kirkpatrick
    Nature Reviews Drug Discovery, 2009, 8 : 21 - 21
  • [8] Targeting Triple-Negative Breast Cancer
    Saljoughian, Manouchehr
    US PHARMACIST, 2020, 45 (10) : 6 - 8
  • [9] The irreversible c-Jun N-terminal kinase (JNK) inhibitor, JNK-IN-8, sensitizes basal-like breast cancer cells to lapatinib
    Ebelt, N. D.
    Van den Berg, C. L.
    CANCER RESEARCH, 2013, 73
  • [10] Targeting Akt3 Signaling in Triple-Negative Breast Cancer
    Chin, Y. Rebecca
    Yoshida, Taku
    Marusyk, Andriy
    Beck, Andrew H.
    Polyak, Kornelia
    Toker, Alex
    CANCER RESEARCH, 2014, 74 (03) : 964 - 973
12345